For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

Every year, Fierce’s pharma, biotech, and medtech teams come together to spotlight some of the fiercest women in life s | ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

New York-based health comms agency Calcium+Company is living up to its name, strengthening the bones of its business with the ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...